ArticleBMC infectious diseases2026
Low necessity, high overuse: revisiting empirical vancomycin practices for children in low MRSA prevalence settings.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe overuse of vancomycin as empirical therapy ranged from 62% to 66% worldwide, while the prevalence of proven infections requiring vancomycin was only 11% to 27%. Evidence from Thailand where the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infection is low and remains limited. This study aimed to determine the incidence of confirmed infections requiring vancomycin as definitive therapy among children aged 1 month-18 years receiving vancomycin as empirical therapy, and to identify factors associated with vancomycin necessity.
methodsA single-centre retrospective cohort study was performed, which included 532 children receiving at least one dose of vancomycin as empirical therapy at a university hospital during 2014–2024. Demographic data, provisional diagnosis, ICU admission, haemodynamic status, presence of central venous catheters, and microbiological results were collected. Factors associated with proven infections requiring vancomycin were determined by multivariable log-binomial regression.
resultsOnly 29 of 510 (5.68%) patients who had empirical treatment with vancomycin truly needed vancomycin as definitive treatment. Provisional diagnosis of device-associated infection, especially cerebrospinal fluid shunt (RR 6.97, 95%CI 2.92–16.63), and intra-abdominal infection following liver transplantation (RR 4.95, 95%CI 1.97–12.48), were significantly associated with proven infections requiring vancomycin in multivariable analysis. Febrile neutropenia, haemodynamic instability, and the presence of central venous catheters were not significantly associated with vancomycin necessity in univariate analysis.
conclusionsIn a setting with a low prevalence of MRSA infection, most patients who received empirical vancomycin were subsequently found not to require it, highlighting the potential for more targeted empirical vancomycin use, such as patients with cerebrospinal fluid shunts or post-liver transplantation intra-abdominal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.